REAGENTS FOR DRUG TOXICITY STUDIES USING MEGAKARYOCYTES

产品说明： 造血干/祖细胞特异性无蛋白表达的研究进展 支持巨核细胞形成的试剂将是不可估量的 重要性 开发这种试剂的基本原理是， 允许测量处于未结合状态的药物毒性， 药物是活跃的。 这种试剂的优点是它们将 作为此类测定的统一标准试剂，节省研究者时间 并努力开发此类试剂，促进药物评价 没有毒品 这项建议结合了两个方面的优点 实验室，一个熟练的开发无蛋白质和无血清 试剂和其他巨核细胞检测试剂。 这样的组合 这对这项提议的成功是个好兆头。 第一阶段的努力 将专注于开发用于小鼠的定义试剂 巨核细胞检测，如果时间允许，在第二阶段的努力 用于人巨核细胞测定的确定试剂的开发。

DESCRIPTION: The development of hematopoietic defined protein-free reagents that support megakaryocyte formation will be of inestimatable importance. The rationale for developing such reagents is that it will allow the measurement of drug toxicity in its unbound state in which all of the drug is active. The advantages to such reagents are they will be uniform standard reagents for such assays, save investigator time and effort in developing such reagents and facilitate drug evaluation free of bond drug. This proposal combines the strengths of two laboratories, one skilled in development of protein-free and serum-free reagents and the other in megakaryocyte assay. Such a combination should bode well for the success of this proposal. The Phase I effort will focus on the development of defined reagents for a murine megakaryocyte assays and, as time permits, and in the Phase II effort the development of defined reagants for human megakaryocyte assays.